Mortality rate
A total of five studies involving 1224 patients reported cases of death
among COVID-19 patients receiving Infliximab or no Infliximab. The
pooled analysis of these studies revealed no significant difference in
mortality rates between the Infliximab and no Infliximab groups (RR=
0.70, 95% CI: 0.53 to 0.91; P < 0.001, I2 = 0%) (Figure 2).